Oncolytics Biotech Inc T.ONC

Adlai Nortye

[lonc17]

From Adlai's website (emphasis mine).  If this is true then it will be about $80 million upfront to ONC, if I remember correctly.  Perhaps someone can confirm the payment. 

https://en.adlainortye.com/index.php/product_info?id=3

Phase II studies have shown an approximate doubling of OS in HR+/HER2-mBC patients who received AN1004. We received the approval from the NMPA in February 2019 for our initiation of an open-label, randomized, multi-center, Phase III clinical trial for AN1004 in combination with paclitaxel in patients with HR+/HER2-mBC. We initiated a bridging trial in China in March 2021 to assess the safety and tolerability of AN1004 in combination with paclitaxel for the Chinese patient population with HR+/HER2- mBC. We plan to initiate Phase III clinical trials in China in the first half of 2022.

[lonc17]

RIght, the dollar numbers are not anywhere near what I remembered.  Nevertheless, with the pace that Adlai can enroll patients, we could see an approval in China within two years.  And news of "first patient enrolled in phase 3" has to bump the share price up... hopefully! One common share purchase warrant of USD $2 million whereby, upon exercise, Adlai may

[lonc17]

Case in point.  Patient recruitment two to three times faster (China vs. U.S). https://www.clinicalleader.com/doc/report-reflects-huge-growth-of-clinical-trials-in-china-0001

[askretka]

Good link interesting. China is way behind USA in using immunotherapy as well so potential growth rate over next decade is a lot more percentage wise and more lucrative for a successful product. From now to 2030 growth in immunotherapy will be 6-8 X but China/ Asia growth rate more like 18- 20X over same period. Cheers!!!

[Noteable]

This appears to be a Good Luck move with Adlai Nortye announcing Good News prior to Chinese New Year and the Year of the Tiger which is associated with bravery, confidence, and strength, as well as being strong-willed and stubborn Good news is also presented in how China is moving quickly in enrolling and advancing clinical trials to completiona and fruition. Good news for both AN and ONCY.

[askretka]

Yes that's interesting. I thought initial plan was to do study in parallel with phase 3 in North America/ Europe but it looks like that might not be the case. It's a new recent update to their website so they might be going ahead with it. It's a separate deal and they aren't subject to same FDA guidelines I'm guessing. There's definitely enough data to show that it's